{"filings":[{"id":1276436,"accession_number":"0001108205-26-000071","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-06-25T20:01:37+00:00","items":["5.07"],"status":"ready","headline":"Curis shareholders approve reverse stock split authorization up to 1-for-25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["26.9M votes for, 752K against, 124K abstain on reverse split proposal.","Board may set ratio between 1:5 and 1:25, or abandon the amendment.","Adjournment proposal also passed but not needed as main proposal carried.","Reverse split intended to meet Nasdaq listing requirements; ratio TBD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609156,"accession_number":"0001108205-26-000065","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-05-22T20:02:14+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Curis stockholders approve doubling of authorized common shares to 567.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased to 567,514,300 from 283,757,150; total capital stock to 572,514,300.","Certificate of Elimination filed to remove Series A and Series B preferred stock designations.","Class III directors Martyn Greenacre and Kenneth Kaitin elected with >20M votes for each; say-on-pay passed with 16.4M for.","PwC ratified as auditor for FY2026 (23.5M for); charter amendment approved with 21.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40083,"accession_number":"0001108205-26-000059","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-05-12T20:01:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.","No revenue in Q1 2026 after sale of Erivedge royalties in Q4 2025; Q1 2025 had $2.4M royalty revenue.","Cash and equivalents $15.0M as of Mar 31; expects runway into H2 2027 contingent on $20.2M Series B warrant exercise.","Closed $80.8M private placement in Jan 2026; initial $20.2M received; warrants exercisable at $0.75 per share.","TakeAim CLL combination trial with zanubrutinib expects dosing of 5th patient mid-2026; PCNSL data in 1H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91341,"accession_number":"0001108205-26-000056","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Curis receives Nasdaq delisting notice due to bid price below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Delist Determination Letter from Nasdaq on April 27, 2026.","Bid price closed below $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2).","Trading suspension scheduled for May 6, 2026 unless appeal is made by May 4, 2026.","Company intends to request a hearing before Panel to stay delisting; outcome uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101350,"accession_number":"0001108205-26-000030","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q4 net income $19.4M on Erivedge gain; PIPE raises $20.2M initial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $7.6M ($0.58/shr) vs $43.4M ($6.88/shr) in FY2024; Q4 net income $19.4M ($1.23/shr).","Sold Erivedge royalty assets for $2.5M upfront and liability release; recognized $27.2M non-cash gain in Q4.","Cash $5.1M at Dec 31; Jan 2026 PIPE raised $20.2M initial, up to $20.2M more from Series B warrants; runway into H2 2027.","Initiated Phase 2 CLL study of emavusertib + zanubrutinib; PCNSL trial: 100% ORR in BTKi-naïve (5/5) patients.","AML triplet study: 62.5% of patients (5/8) achieved MRD conversion to undetectable after adding emavusertib to aza-ven."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101349,"accession_number":"0001108205-26-000016","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Curis shareholders approve authorized share increase from 73.3M to 288.8M and 2026 Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 68.3M to 283.8M; total capital stock from 73.3M to 288.8M, effective March 17, 2026.","Stockholders approved issuance of shares upon conversion of Series B Preferred and exercise of Series A, B, C Warrants (4.0M for, 774K against).","2026 Incentive Plan approved: initial reserve of 6.4M shares plus evergreen provision (3.2M for, 1.3M against, 286K abstain).","Adjournment proposal passed (6.7M for) to allow further proxy solicitation if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101348,"accession_number":"0001108205-26-000006","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Curis regains Nasdaq compliance but faces one-year discretionary monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 3, 2026 that it regained compliance with MVLS Rule (Rule 5550(b)(2)).","Subject to a one-year Discretionary Panel Monitor; full compliance with Hearings Panel terms.","If non-compliant again during monitoring, Staff will issue Delist Determination Letter immediately.","Company retains right to request new hearing before panel if delisting is determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101347,"accession_number":"0001108205-26-000002","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Curis raises up to $80.8M in PIPE financing; extends cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial gross proceeds of ~$20.2M from sale of Series B Preferred Stock and warrants; potential total up to ~$80.8M if warrants exercised.","Warrants to purchase up to 26.9M shares each (Series A, B, C) at $0.75 exercise price; exercisable after stockholder approval.","Proceeds expected to extend cash runway into 2027; focus on Phase 2 combo study of emavusertib in CLL and PCNSL.","Purchasers include CEO, CFO, CMO, CDO and a board member.","PIPE proceeds believed to sustain stockholders’ equity above Nasdaq $2.5M minimum; delisting hearing pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117716,"accession_number":"0001108205-25-000111","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K/A","filed_at":"2025-11-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Curis sells Erivedge royalty interest for $2.5M; pro forma shows $28M gain","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Curis Royalty LLC to Oberland Capital for $2.5M upfront plus release of $28.6M liability.","Pro forma 9M 2025 net loss of $33.2M vs reported $26.9M due to eliminated revenue.","Company to recognize ~$28M gain in Q4 2025 on extinguishment of liability.","Future Erivedge license revenue eliminated; company no longer entitled to royalties.","Pro forma cash $11.5M vs reported $9.1M; total assets reduced to $26.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117718,"accession_number":"0001108205-25-000105","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.02","2.01","2.02","8.01","9.01"],"status":"ready","headline":"Curis sells Erivedge royalty rights to Oberland for $2.5M; Q3 net loss narrows to $7.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Erivedge IP and license rights to Oberland affiliate for $2.5M upfront and release of future royalty liability.","Q3 2025 net loss $7.7M ($0.49/sh), improved from $10.1M loss in Q3 2024.","Revenue from Erivedge royalties $3.2M in Q3; company will recognize gain but no future Erivedge revenues.","Cash $9.1M as of Sep 30; expects to fund operations into early 2026.","Nasdaq granted extension to Nov 14 to regain MVLS compliance; company believes equity now exceeds $2.5M threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117717,"accession_number":"0001108205-25-000098","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants Curis exception until Nov 14, 2025 to meet $35M MVLS rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq delisting notice on Aug 21, 2025 for failing $35M market value requirement.","After appeal, Panel granted exception until Nov 14, 2025 to regain compliance.","Company must promptly notify Nasdaq of any significant events during exception period.","No assurance that Company will ultimately regain compliance and remain listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134164,"accession_number":"0001108205-25-000093","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Curis receives Nasdaq delisting notice for market value below $35M; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Aug 21, 2025, Curis received Nasdaq delisting notice for failing MVLS Requirement (market value <$35M for 30 consecutive days).","Company intends to request a hearing before Nasdaq Hearings Panel by Aug 28 to appeal the determination.","Stock remains listed and trading on Nasdaq pending Panel's decision; no assurance of regaining compliance.","Original non-compliance notice received Feb 21, 2025; 180-day Compliance Period ended Aug 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134163,"accession_number":"0001108205-25-000087","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Curis files prospectus supplement for up to $8.14M common stock ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $8,137,047 in common stock offered via ATM under existing Sales Agreement with Cantor Fitzgerald & JonesTrading.","Prior $100M prospectus terminated July 1, 2025; new prospectus supplement filed August 8, 2025.","Legal opinion from Wilmer Cutler Pickering Hale and Dorr LLP filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134162,"accession_number":"0001108205-25-000079","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q2 2025 net loss $8.6M; cash runway extended to Q1 2026 via $6M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.6M ($0.68/sh) vs $11.8M ($2.03/sh) in Q2 2024; revenue $2.7M from Erivedge royalties.","Cash and equivalents $10.1M at June 30, 2025; July 2025 offerings added ~$6M net proceeds.","TakeAim Lymphoma study enrolling PCNSL patients to support US/EU accelerated approval; data expected later 2025.","Adding proof-of-concept CLL study of emavusertib + BTKi in 20-30 R/R patients; enrollment to begin later 2025.","TakeAim Leukemia Phase 1/2 enrollment complete; designing registrational trial vs gilteritinib in R/R AML."],"consensus_eps_estimate":-0.9078,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":5129000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134161,"accession_number":"0001108205-25-000072","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Curis raises $7.0M in registered direct & private placement; cash runway into Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$7.0M from sale of 1,538,460 shares and warrants; combined price $2.275/share + warrant.","Pre-funded warrants at $0.01 exercise price; common warrants at $2.15, 5-year term.","Cash runway expected into Q1 2026 based on current plans; ATM program terminated.","Underwriter fees ~$0.5M plus expenses up to $0.1M.","Offering expected to close July 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150921,"accession_number":"0001108205-25-000053","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Curis shareholders approve doubling of authorized common shares, quorum reduction, and equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 34.2M to 68.3M; total capital stock from 39.2M to 73.3M.","Bylaws amended to reduce stockholder meeting quorum from majority to one-third of outstanding shares.","Stock incentive plan amended to reserve an additional 1.255M shares, total now 3.356M shares.","Shareholders approved issuance of up to 8.317M shares upon exercise of warrants issued March 31, 2025.","Directors Hohneker and Rubin re-elected; advisory say-on-pay passed; PwC ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150920,"accession_number":"0001108205-25-000045","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q1 net loss $10.6M, appoints Dr. Hamdy CMO, emavusertib progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.6M ($1.25/share); cash $20.3M; runway into Q4 2025.","Revenue $2.4M from Genentech/Roche Erivedge royalties.","Appointed Dr. Ahmed Hamdy (ex-Pharmacyclics, Acerta) as CMO.","FDA & EMA meetings support accelerated approval path for emavusertib in PCNSL.","Completed registered direct offering and private placement with net proceeds ~$8.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2380000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169837,"accession_number":"0001108205-25-000028","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis gains FDA & EMA support for accelerated approval of emavusertib in PCNSL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA and EMA agree TakeAim Lymphoma study may support accelerated approval path for PCNSL.","Emavusertib granted Orphan Drug Designation for PCNSL in both US and EU.","In 20 BTKi-experienced PCNSL patients: 6 objective responses, 4 complete responses.","Q4 2024 net loss $9.6M ($1.25/share); FY2024 net loss $43.4M ($6.88/share).","Cash $20.0M at Dec 31, 2024; plus $10M from March 2025 offerings funds ops into Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2380000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169836,"accession_number":"0001108205-25-000022","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Curis raises ~$10M; FY2024 net loss $43.4M; FDA/EMA see path for PCNSL drug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from sale of 1.97M shares and pre-funded warrants for 2.18M shares, plus common warrants for 8.32M shares at $2.41.","FY2024 net loss $43.4M ($6.88/share) vs $47.4M in 2023; revenue $10.9M vs $10.0M; cash $20.0M at Dec 31, 2024.","Cash runway extended into Q4 2025 with offering net proceeds combined with existing cash.","FDA and CHMP guidance supports potential accelerated/conditional approval for emavusertib in PCNSL; 9 of 13 BTKi-experienced evaluable patients had tumor reduction with 4 CRs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169835,"accession_number":"0001108205-25-000020","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Curis receives Nasdaq notice of non-compliance with market value listing requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Market value of listed securities below $35M for 30 consecutive business days as of Feb 21, 2025.","Company has 180 calendar days (until Aug 20, 2025) to regain compliance.","To regain compliance, closing market value must be $35M or more for 10 consecutive business days.","If not cured, Nasdaq will issue delisting notice for Curis common stock (CRIS).","Company cautions there is no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186902,"accession_number":"0001108205-24-000071","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q3 net loss narrows to $10.1M; emavusertib shows durable responses in BTKi-progressed PCNSL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.1M ($1.70 per share) vs $12.2M ($2.13) in Q3 2023; nine-month net loss $33.8M.","Revenue $2.9M from Erivedge royalties, essentially flat YoY.","Cash $31.6M after $10.8M October offering; expects runway into mid-2025.","Emavusertib in PCNSL: 3 CR + 1 CRu + 2 PR among 10 BTKi-progressed patients; 3 responses >6 months.","Oral and poster presentations on emavusertib in AML/MDS at ASH in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":7563000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186901,"accession_number":"0001108205-24-000068","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Curis raises $12.1M via registered direct offering and concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,398,414 shares of common stock and unregistered warrants for 2,398,414 shares at exercise price $4.92.","Combined purchase price per share and associated warrant is $5.045; gross proceeds ~$12.1M before fees.","Offering expected to close on or about October 30, 2024; Truist Securities and Laidlaw & Company acting as placement agents.","Net proceeds plus existing cash expected to fund operations into mid-2025; use for R&D and working capital.","Warrants are exercisable immediately for 5 years with customary beneficial ownership limitation of 4.99%/9.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203434,"accession_number":"0001108205-24-000061","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q2 net loss $11.8M; emavusertib gets EU ODD for PCNSL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.8M ($2.03/sh) vs $12.0M ($2.47) in Q2 2023; revenue $2.5M from Erivedge royalties.","Cash, equivalents and investments $28.4M; expected to fund operations into Q1 2025.","EC granted Orphan Drug Designation to emavusertib for treatment of primary CNS lymphoma.","Initial data for 15-20 R/R PCNSL patients expected late 2024; ASH presentation planned.","Updated TakeAim Leukemia data and frontline triplet combo safety data due late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":4632000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219838,"accession_number":"0001108205-24-000047","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","8.01","9.01"],"status":"ready","headline":"Curis cuts workforce ~30%, focuses on combo studies; cash runway into 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved ~30% workforce reduction as monotherapy trials near completion.","Company focusing on combination studies in CNS lymphoma and front-line AML.","Expects no significant 2024 cost impact; cost reductions anticipated in 2025.","Stockholders approved increasing authorized common shares to 34,171,875.","Stockholders approved additional 942,100 shares for 2010 Stock Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219837,"accession_number":"0001108205-24-000035","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Curis expands TakeAim Leukemia study to 30 patients; 6/11 FLT3m and 4/18 SFm respond","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TakeAim Leukemia dataset expanded from 5 to 30 R/R AML patients (25 new) with emavusertib monotherapy at 300 mg BID.","FLT3m cohort: 6/11 evaluable patients achieved objective response (3 CR, 1 CRh, 2 MLFS); responses mostly in one cycle.","SFm cohort: 4/18 evaluable patients achieved objective response (1 CR, 2 CRh, 1 MLFS); 3 additional patients showed increased neutrophils.","All responders had complete bone marrow blast normalization; two patients proceeded to allogenic stem cell transplant.","Curis discloses insufficient cash to fund operations for next 12 months, highlighting need for additional capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219836,"accession_number":"0001108205-24-000032","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q1 net loss $11.9M ($2.05/sh); cash $40.7M; topline AML data May 14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M vs $11.6M Q1 2023; revenue $2.1M (Erivedge royalties) vs $2.3M.","Cash, equivalents and investments $40.7M as of March 31, 2024; expected to fund operations into 2025.","Topline clinical data from TakeAim Leukemia study (emavusertib monotherapy in R/R AML) to be released May 14, 2024.","Abstracts accepted for ASCO (May 31-Jun 4) and EHA (Jun 13-16); posters on FLT3m and mSF cohorts.","Updated data for R/R PCNSL and frontline AML triplet combo expected late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2086000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239607,"accession_number":"0001108205-24-000008","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q4 2023 net loss $11.7M ($2.03/sh); cash $56.3M, clinical data from ASH shows CRs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2023 was $11.7M ($2.03/share) vs $11.3M ($2.35/share) in Q4 2022.","Revenue from Erivedge royalties was $2.7M for Q4 2023, flat YoY.","Cash & investments totaled $56.3M at Dec 31, 2023; company expects runway into 2025.","At ASH, emavusertib + ibrutinib achieved CR in 3 of 5 evaluable R/R PCNSL patients after BTKi failure.","Updated TakeAim Leukemia data expected H1 2024; lymphoma combo and triplet combo data in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":10023000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239606,"accession_number":"0001108205-24-000003","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Curis files updated corporate slide presentation; no material new details evident","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate slide presentation under Item 7.01, dated January 2024.","Presentation content is not disclosed in the filing; no specific financial or strategic changes mentioned.","No earnings, guidance, or operational metrics are provided in this filing or exhibit snippet.","Investors should review the full presentation for any updates on pipeline or partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257125,"accession_number":"0001108205-23-000073","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q3 net loss $12.2M ($2.13/sh); cash $68.5M; emavusertib studies resume","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $12.2M from $13.3M YoY; revenue unchanged at $2.8M from Erivedge royalties.","Cash, cash equivalents and investments total $68.5M; company expects funding into 2025.","Patient enrollment restarted in Phase 1/2 TakeAim Leukemia and Lymphoma emavusertib studies after partial clinical hold lift.","Plans to initiate triplet combo study of emavusertib with azacitidine and venetoclax in AML in Q4 2023.","Updated TakeAim Lymphoma data expected at ASH December 2023; leukemia data in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":7327000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274456,"accession_number":"0001108205-23-000066","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Curis approves 1-for-20 reverse stock split; authorized common shares set at 22.78M after amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Sept 26, 2023 approved 1-for-20 reverse stock split; effective Sept 28, trading on split-adjusted basis Sept 29.","Stockholders also approved increase in authorized capital stock from 232.8M to 460.6M and common from 227.8M to 455.6M before reverse split.","After reverse split, authorized common shares reduced proportionately to 22,781,250; fractional shares rounded up.","Board determined ratio of 1-for-20 following stockholder approval; reverse split does not change par value or preferred shares.","Vote results: reverse split 73.0M for vs 12.3M against; authorized shares increase 71.4M for vs 13.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274452,"accession_number":"0001108205-23-000069","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K/A","filed_at":"2023-09-28T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Curis stockholders approve 1-for-20 reverse stock split and increase in authorized shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 227,812,500 to 455,625,000 at Special Meeting on Sept 26.","Board set reverse stock split at 1-for-20; effective 5:00 p.m. ET on Sept 28, trading on split-adjusted basis begins Sept 29.","After reverse split and proportionate reduction, authorized common shares become 22,781,250.","Reverse split proposal passed with 73M for, 12M against; authorized shares proposal passed with 71M for, 14M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274455,"accession_number":"0001108205-23-000059","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q2 net loss $12.0M ($0.12/sh); FDA lifts partial clinical hold on TakeAim Leukemia study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.0M ($0.12/sh) vs $15.9M ($0.17/sh) in Q2 2022; six-month net loss $23.5M ($0.24/sh).","Revenue $2.2M from Erivedge royalties; R&D expense $10.0M (down 19% YoY), G&A $4.2M (down 18% YoY).","FDA removed partial clinical hold on emavusertib TakeAim Leukemia study; confirmed RP2D at 300 mg BID.","Cash, equivalents and investments $77.4M after July registered direct offering ($13.8M net); runway into 2025.","Updated clinical data from monotherapy and combination studies expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":4494000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274454,"accession_number":"0001108205-23-000056","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Curis prices $15.1M registered direct offering of 18.4M shares at $0.82/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering led by existing investors; 18.4M shares sold at $0.82 per share.","Gross proceeds ~$15.1M; closing expected July 10, 2023.","Net proceeds for R&D, working capital, and general corporate purposes.","Cantor Fitzgerald and Truist Securities acting as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274453,"accession_number":"0001108205-23-000054","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts partial clinical hold on Curis leukemia study; RP2D set at 300 mg BID","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed partial clinical hold on TakeAim Leukemia Phase 1/2 study of emavusertib (CA-4948).","Recommended Phase 2 dose (RP2D) for monotherapy established at 300 mg BID in AML/MDS patients.","At 300 mg BID, 2 of 3 FLT3-mutant AML patients achieved CR; 2 of 3 spliceosome-mutant achieved CR/CRh.","Company plans to enroll targeted AML patients and initiate front-line combination study with azacitidine/venetoclax.","Expects updated monotherapy data, registrational study design, and initial combo data in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291722,"accession_number":"0001108205-23-000051","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Curis shareholders elect directors, approve say-on-pay, and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martyn D. Greenacre and Kenneth I. Kaitin elected as Class III directors with 30.4M and 26.8M votes for, respectively.","Nonbinding advisory vote on executive compensation approved with 27.7M for, 2.9M against.","Shareholders recommended future say-on-pay votes every 1 year with 30.1M votes for that frequency.","Ratification of PricewaterhouseCoopers as auditor for FY2023 passed with 60.4M for, 818k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291721,"accession_number":"0001108205-23-000048","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q1 net loss narrows to $11.6M; enrolls 9 patients for emavusertib; new CDO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.6M ($0.12/share) vs $16.1M ($0.18) YoY; revenue $2.3M, up from $2.1M.","Enrolled 9 additional patients at 200mg BID for emavusertib; FDA partial clinical hold discussion expected in Q3 2023.","Appointed Jonathan Zung, Ph.D. as Chief Development Officer effective May 1, 2023; previously CDO at Evelo.","Cash and investments $71.8M as of Dec 31, 2022; cash runway expected into 2025.","R&D expenses down to $9.1M from $11.4M; G&A down to $4.8M from $5.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2297000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291720,"accession_number":"0001108205-23-000040","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Curis receives Nasdaq approval to transfer to Capital Market; extended bid-price compliance deadline to Oct 16, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Transfer from Nasdaq Global Market to Nasdaq Capital Market effective April 24, 2023.","Extended compliance period until October 16, 2023 to regain $1.00 minimum bid price.","Company had 180-day initial period from Oct 21, 2022 that expired Apr 19, 2023.","To regain compliance, stock must close at $1.00+ for at least 10 consecutive business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312499,"accession_number":"0001108205-23-000022","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","5.03","9.01"],"status":"ready","headline":"Curis completes FDA-requested enrollment for emavusertib; FY2022 net loss $56.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment of 9 additional patients at 200mg BID for TakeAim Leukemia study ahead of schedule; expects data in Q2, FDA meeting in Q3 for partial clinical hold resolution.","Net loss for FY2022 was $56.7M ($0.61 per share) vs $45.4M ($0.50) in 2021; Q4 net loss $11.3M ($0.12) vs $13.6M ($0.15) in Q4 2021.","Revenue from Erivedge royalties was $10.2M in FY2022 vs $10.6M; cash and investments $85.6M as of Dec 31, 2022, expected to fund operations into 2025.","R&D expenses increased to $43.3M from $34.9M in FY2022; company focused resources on emavusertib development.","Board adopted amended bylaws including exclusive forum provision and enhanced stockholder nomination requirements; advance notice deadline for 2024 annual meeting changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331030,"accession_number":"0001108205-22-000022","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q3 net loss $13.3M, cuts ~30% of workforce to focus on emavusertib, cash runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.3M ($0.14/shr) vs $11.1M ($0.12/shr) in Q3 2021; revenues $2.8M.","Plan to reduce workforce by ~30% and reallocate resources to emavusertib pipeline.","Cash & equivalents $98.7M as of Sep 30; expects cash runway into 2025.","Updated TakeAim Leukemia data for emavusertib to be presented at ASH 2022 (Dec 10-13).","FDA has allowed enrollment to resume in TakeAim Lymphoma and monotherapy dose finding of TakeAim Leukemia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":7275000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331029,"accession_number":"0001108205-22-000018","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Curis receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Oct 21, 2022, Nasdaq notified Curis its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).","Curis has 180 calendar days, until April 19, 2023, to regain compliance by closing at $1.00 or more for at least 10 consecutive business days.","If not compliant by April 19, 2023, Curis may transfer to Nasdaq Capital Market for an additional 180-day period, subject to meeting other listing standards.","Failure to regain compliance or qualify for an extension could result in delisting; Curis may appeal to a Nasdaq Listing Qualifications Panel.","The company intends to monitor its stock price and may consider available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331028,"accession_number":"0001108205-22-000016","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Curis elects Anne E. Borgman, M.D. to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anne E. Borgman, M.D. elected as Class I director effective Oct 12, 2022, term until 2024 annual meeting.","She will serve on the Nominating and Corporate Governance Committee immediately.","Granted one-time option for 25,000 shares vesting over 4 years with 10-year term.","Entered standard indemnification agreement with Curis consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348577,"accession_number":"0001108205-22-000012","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Lori Kunkel resigns from Curis board citing fundamental disagreement on operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective September 30, 2022; she served on Nominating/Corporate Governance and chaired Clinical Program Committee.","Resignation attributed to fundamental difference in belief on company operations.","Company provided Dr. Kunkel opportunity to furnish letter confirming or disagreeing with company's statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348576,"accession_number":"0001193125-22-233468","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA allows Curis to resume enrollment in Phase 1a of emavusertib leukemia study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removed partial clinical hold on monotherapy dose-finding (Phase 1a) of TakeAim Leukemia study after reviewing rhabdomyolysis data.","At least nine additional patients will be enrolled at the 200 mg dose level in Phase 1a.","Partial hold remains on combination phase (Phase 1b) and expansion phase (Phase 2a) until FDA approves progression.","Rhabdomyolysis side-effect management strategy was key to FDA clearance; similar to approach used with Odomzo and Cotellic.","Preliminary clinical data update from TakeAim Leukemia study expected in 2023; company engaging FDA leukemia division on optimal dose and development path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348575,"accession_number":"0001193125-22-223699","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts partial clinical hold on Curis's TakeAim Lymphoma study of emavusertib","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted partial clinical hold on TakeAim Lymphoma Phase 1/2 study; enrollment to resume Q3 2022.","Partial hold on TakeAim Leukemia study remains under FDA Division of Hematologic Malignancies 1.","Hold lifted after FDA agreement on rhabdomyolysis management and enrollment of ≥9 patients at 200 mg emavusertib plus ibrutinib.","Preliminary clinical data update from TakeAim Lymphoma expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348574,"accession_number":"0001193125-22-212487","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Curis Q2 net loss widens to $15.9M; appoints new CFO; emavusertib combo shows tumor reduction in 8 of 9","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M ($0.17/sh) vs $10.8M ($0.12) in Q2 2021; revenue flat at $2.4M.","Cash and investments $107.2M as of June 30, 2022; cash runway expected into 2024.","Emavusertib + ibrutinib combo: tumor reduction in 8 of 9 evaluable patients; 2 CR, 2 PR; potential to overcome ibrutinib resistance.","Appointed Diantha Duvall as CFO effective Aug 5, 2022, succeeding Bill Steinkrauss (resigning).","Working with FDA to resolve partial clinical holds on emavusertib enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":4450000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365311,"accession_number":"0001193125-22-186157","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Curis CFO William Steinkrauss resigns effective Aug 5, 2022; consulting transition","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Steinkrauss notified Curis of resignation on June 27, 2022 to pursue entrepreneurial opportunity.","Resignation not due to any dispute with Curis regarding financial reporting, policies, or practices.","Steinkrauss will remain CFO/CAO until Aug 5, 2022; company has begun search for successor.","Consulting agreement post-resignation: $475/hour, minimum 2 days/week through end of 2022.","Company will reimburse pre-approved out-of-pocket expenses related to advisory services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365310,"accession_number":"0001193125-22-166212","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Curis shareholders elect Hohneker but substantial withhold votes for director Rubin at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John A. Hohneker re-elected with 42,274,804 for vs 3,584,620 withheld (23M broker non-votes).","Marc Rubin re-elected with 23,717,040 for vs 22,142,384 withheld — nearly 50% of votes cast opposed.","Say-on-pay advisory proposal approved: 44,039,544 for, 1,760,379 against, 59,501 abstain.","PricewaterhouseCoopers ratified as auditor for FY2022: 68,912,765 for, 107,520 against, 175,491 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365309,"accession_number":"0001564590-22-018292","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Curis Q1 net loss $16.1M; cash $120.7M; emavusertib studies on partial clinical hold","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.1M ($0.18/sh) vs $9.9M in Q1 2021; revenue $2.1M unchanged.","Cash and investments $120.7M; runway into 2024, guidance unchanged.","FDA partial clinical hold on TakeAim Leukemia and Lymphoma studies for emavusertib due to rhabdomyolysis data request.","TakeAim Leukemia data: 40% CR/CRh in spliceosome-mutated AML; 57% ORR in spliceosome-mutated MDS.","CI-8993 (anti-VISTA) dose escalation cleared 0.3mg/kg; now at 0.6mg/kg; RP2D yet to be determined."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":2057000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365308,"accession_number":"0001193125-22-101017","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA partial clinical hold on Curis' TakeAim Lymphoma study; no new enrollment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed partial clinical hold on Phase 1/2 TakeAim Lymphoma study of emavusertib in B-cell malignancies.","No new patients can be enrolled; current participants benefiting may continue at 300mg BID or lower after reconsent.","Hold follows prior partial hold on TakeAim Leukemia study announced April 4, 2022; company had already paused enrollment voluntarily.","FDA requests additional safety, efficacy, and rhabdomyolysis data; company to provide updated guidance after holds resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365307,"accession_number":"0001193125-22-094363","cik":1108205,"company_name":"CURIS INC","ticker":"CRIS","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA partial clinical hold on Curis leukemia study after patient death; lymphoma study paused","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA partial clinical hold on TakeAim Leukemia Phase 1/2a (NCT04278768); no new patients enrolled.","Hold triggered by death of R/R AML patient; rhabdomyolysis identified as dose-limiting toxicity.","Current patients may continue on emavusertib at ≤300mg BID; FDA requests additional safety data.","Curis voluntarily pauses enrollment in TakeAim Lymphoma study (NCT03328078) pending hold resolution.","FDA also requests data on Recommended Phase 2 Dose determination for emavusertib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":20459915.057007577,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-04T23:59:59+00:00|365307"}